- Home
- Latest news
Latest news
Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list
The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.
More from Johnson & Johnson
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Johnson & Johnson named a 2025 Fortune World’s Most Admired Company
A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.
Careers
Looking for a career opportunity at Johnson & Johnson? Search our available jobs.
Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
What is metastatic cancer?
The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.
“The surgical devices I design help speed healing and save lives”
Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.
Press releases
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
Johnson & Johnson reports Q1 2025 results
• 2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* • 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* • Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA • Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition • Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System
First use in gastric bypass at Memorial Hermann-Texas Medical Center Trial will support submission for multiple procedures
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill
ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16
